<DOC>
	<DOCNO>NCT00842556</DOCNO>
	<brief_summary>To assess effect glimepiride PK dapagliflozin effect dapagliflozin PK glimepiride , co-administered healthy subject ( Phase A ) ass effect sitagliptin PK dapagliflozin effect dapagliflozin PK sitagliptin , co-administered healthy subject ( Phase B )</brief_summary>
	<brief_title>Pharmacokinetic Drug Interaction Study Dapagliflozin Glimepiride Sitagliptin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body mass index ( BMI ) 18 32 kg/m2 , inclusive BMI = weight ( kg ) / [ height ( ) ] 2 WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 12 week last dose investigational product Abnormal liver function test ( ALT , AST total bilirubin &gt; 10 % ULN ) History chronic recurrent UTI ( define 3 occurrence per year ) UTI past 3 month History allergy SGLT @ inhibitor , DPP $ inhibitor sulfonylurea related compound Prior exposure dapagliflozin , sitagliptin glimepiride within 3 month Day 1 History recurrent ( defined 3 occurrence per year ) recent vulvovaginal mycotic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>